Kura Oncology Inc (KURA)
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its commercial product is KOMZIFTI (ziftomenib), an oral small-molecule menin inhibitor designed to be selective and reversible. The company is also advancing Darlifarnib, which is being studied in a first-in-human Phase 1 FIT-001 trial across multiple cohorts and in combination with other targeted therapies in large solid tumor indications. In addition, Kura Oncology is developing KO-7246, a next-generation menin inhibitor intended for diabetes and cardiometabolic disorders, along with other next-generation menin inhibitors for use with additional therapies in solid tumors. Kura Oncology is headquartered in San Diego, California, and its common stock is listed on NASDAQ under the ticker KURA.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-KURA
|
$10.71
|
0.6% Upside
|
Fair
|
$31.17
|
192.6% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
-3.2x
|
8.8x
|
13.2x
|
948.1 M
|
388.9 M
|
2.5%
|
79.3%
|
-2.2
|
—
|
28.7%
|
